Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769267 | PMC |
| http://dx.doi.org/10.3892/mco.2017.1489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intraarticular Nodular Fasciitis of the Elbow Confirmed by Gene Fusion.
Int J Surg Pathol
December 2024
Department of Orthopedics, Osaka General Medical Center, Osaka, Japan.
Nodular fasciitis is a benign, usually self-limiting myofibroblastic proliferation with a predilection for the upper extremities, trunk, and head and neck, and almost all of which harbor the fusion. Since nodular fasciitis is not widely recognized to arise within the joints, it may therefore cause diagnostic confusion in this uncommon setting. We report an unusual tumor of an 11-year-old patient who presented with a 6-month history of right elbow swelling and pain.
View Article and Find Full Text PDFEstablishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone.
Hum Cell
December 2024
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Giant cell tumor of bone (GCTB) is a rare osteolytic tumor composed of mononuclear stromal cells, macrophages, and osteoclast-like giant cells. While generally benign, GCTB has a high risk of local recurrence and can occasionally undergo malignant transformation or metastasis, posing significant clinical challenges. The primary treatment is complete surgical resection; however, effective management strategies for recurrent or advanced GCTB remain elusive, underscoring the need for further preclinical research.
View Article and Find Full Text PDFIntroduction: Brown tumors are benign lesions caused by hyperparathyroidism and characterized by increased osteoclast activity and mass effect, which can lead to paraplegia when the spine is involved. Secondary hyperparathyroidism is common in patients on long-term hemodialysis therapy.
Case Report: We report the case of a 48-year-old man on regular dialysis who presented with leg weakness as well as back pain and was diagnosed with secondary hyperparathyroidism and thoracic spine tumor.
PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE.
J Ayub Med Coll Abbottabad
December 2024
Combined Military Hospital, Rawalpindi-Pakistan.
Article Synopsis
- Giant cell tumour of bone (GCTB) is a rare benign tumor that mainly affects young adults (ages 20-40) and is classified as an intermediate malignant tumor by the WHO, with its pathology linked to the expression of RANKL.
- A study conducted over 36 months at a military hospital investigated the effects of preoperative denosumab therapy on GCTB patients, measuring pain and functional status before and after treatment.
- Results showed significant improvement in pain and function, shifting the intended surgical approach from more invasive procedures like joint resection to less aggressive options such as intralesional curettage post-denosumab therapy.
Conventional (bone-type) giant cell tumor of the larynx: the first case with proven H3-3A: c.103G >T (p.Gly35Trp) mutation.
Virchows Arch
November 2024
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
This report documents the first case of a conventional (bone-type) giant cell tumor of the larynx, in which the diagnosis was confirmed by molecular genetic analysis. A 50-year-old non-smoking man experienced progressive hoarseness lasting for 3 months. Imaging showed a 40-mm tumor arising from the right thyroid cartilage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!